Restructuring, Impairment, and Related Charges, Net (Tables)

6 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

Restructuring, Impairment, and Related Costs

Restructuring, impairment, and related charges, net, for the three months ended September 30, 2022 and 2021 consisted of the following:

	Three Months Ended September 30, 2022
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Severance and employee-related costs, net	$	—	$	—	$	—	$	2	$	(5)	$	(3)
Exit and other-related costs (1)	—		1		1		6		14		22
Asset impairments and accelerated depreciation	3		6		—		1		1		11
Total	$	3	$	7	$	1	$	9	$	10	$	30

(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Three Months Ended September 30, 2021
(In millions)	U.S. Pharmaceutical (1)		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate (1)		Total
Severance and employee-related costs, net	$	—	$	(1)	$	1	$	(2)	$	1	$	(1)
Exit and other-related costs (2)	2		1		—		1		6		10
Asset impairments and accelerated depreciation	8		—		1		2		12		23
Total	$	10	$	—	$	2	$	1	$	19	$	32

(1)Includes costs related to the transition to a partial remote work model described above.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Restructuring, impairment, and related charges, net, for the six months ended September 30, 2022 and 2021 consisted of the following:

	Six Months Ended September 30, 2022
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Severance and employee-related costs, net	$	3	$	—	$	—	$	2	$	(6)	$	(1)
Exit and other-related costs (1)	1		3		2		8		29		43
Asset impairments and accelerated depreciation	3		11		—		1		(4)		11
Total	$	7	$	14	$	2	$	11	$	19	$	53

(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Six Months Ended September 30, 2021
(In millions)	U.S. Pharmaceutical (1)		Prescription Technology Solutions (1)		Medical-Surgical Solutions (1)		International (2)		Corporate (1)		Total
Severance and employee-related costs, net	$	2	$	(1)	$	1	$	10	$	1	$	13
Exit and other-related costs (3)	4		2		2		15		27		50
Asset impairments and accelerated depreciation	16		17		5		36		53		127
Total	$	22	$	18	$	8	$	61	$	81	$	190

(1)Includes costs related to the transition to a partial remote work model described above.

(2)Includes costs related to the transition to a partial remote work model described above, U.K. operating model and cost optimization efforts, and costs for optimization programs in Canada.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2022:

(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Balance, March 31, 2022 (1)	$	11	$	3	$	1	$	56	$	59	$	130
Restructuring, impairment, and related charges, net	7		14		2		11		19		53
Non-cash charges	(3)		(11)		—		(1)		4		(11)
Cash payments	(3)		(3)		(2)		(6)		(25)		(39)
Other (2)	(1)		—		—		(24)		1		(24)
Balance, September 30, 2022 (3)	$	11	$	3	$	1	$	36	$	58	$	109

(1)As of March 31, 2022, the total reserve balance was $130 million, of which $58 million was recorded in “Other accrued liabilities,” $36 million was recorded in “Liabilities held for sale,” and $36 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.

(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. For the Company’s International segment, other also includes a reduction of the liability related to the sale of the U.K. disposal group in April 2022, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”

(3)As of September 30, 2022, the total reserve balance was $109 million, of which $60 million was recorded in “Other accrued liabilities,” $22 million was recorded in “Liabilities held for sale,” and $27 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.